GTx reports PhII results; Genentech CEO leaves Dendreon board;

@FierceBiotech: Pfizer: Pipeline will redeem underperforming labs. Report | Follow @FierceBiotech

@JohnCFierce: For anyone interested, here are the 2009 and 2008 Fierce 15 winners. @JohnCFierce

> GTx says a Phase II trial of GTx-758 for advanced prostate cancer suppressed serum total testosterone to castrate levels, increased serum SHBG (sex hormone binding globulin), and reduced serum free testosterone in healthy male volunteers. Article

> PATH has received a $5.2 U.S. contract $5.2 million contract to support development of flu vaccines remain effective for years, according to XconomyReport

> Seattle-based Dendreon (NASDAQ: DNDN) said that Ian Clark, CEO of Roche's U.S.-based Genentech unit, is resigning from the Dendreon board. Dendreon release | Story

> Even as it moves to shed 1,000 jobs by the end of next year, Genzyme is accelerating the hiring of manufacturing and quality control workers in Massachusetts, where it recently built a plant in Framingham and expanded its Allston Landing site. News

And Finally... Researchers at Concordia University have found that a bile acid called lithocholic acid (LCA), can extend the lifespine of normally aging yeast. The findings may have implications for human longevity and health. Release

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.